Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant [Phase 2]
A Phase 2 clinical trial is evaluating the combination of belantamab mafodotin and lenalidomide in patients with multiple myeloma who remain…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2) [Phase 1]
Phase I, open-label, multicenter study to evaluate safety, tolerability, cellular kinetics, immunogenicity, pharmacodynamics, and preliminar…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Hypofractionation (Radiation) Trial for Multiple Myeloma [Phase 1]
A Phase 1 clinical trial at the University of Chicago is evaluating hypofractionation radiation therapy for multiple myeloma and is currentl…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Isatuximab in Combination With Novel Agents in RRMM - Master Protocol [Phase 1, Phase 2]
A master protocol trial evaluating Isatuximab in combination with novel agents for relapsed/refractory multiple myeloma is in Phase 1/2 and …
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]
This is a Phase 1 clinical trial evaluating intravenous etentamig in combination with an oral CELMoD agent for adults with relapsed or refra…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Older Patients Undergoing CAR-T Therapy for Relapsed or Refractory Multiple Myeloma [NA]
This clinical trial assesses whether a prehabilitation program combining aerobic and resistance exercise improves physical fitness and quali…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
A clinical trial registry update from Dana-Farber Cancer Institute notes a study involving questionnaires and tissue banking for multiple my…
-
CLINICAL_TRIALS trial_result · 2026-03-30Clinical Trial Update: A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma [EARLY_Phase 1]
An early-phase 1 clinical trial of IMV102 for relapsed/refractory multiple myeloma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-27Clinical Trial Update: Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma [Phase 2]
Phase 2 study evaluating a quadruplet regimen of isatuximab, pomalidomide, elotuzumab, and dexamethasone for relapsed/refractory multiple my…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]
A Phase 1 clinical trial update assessing the safety (adverse events) and preliminary activity of ABBV-383 given by subcutaneous injection i…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma [Phase 3]
Phase 3 trial evaluating Anitocabtagene Autoleucel versus standard of care in relapsed/refractory multiple myeloma; recruitment is ongoing.
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
A clinical trial is evaluating Epunamin in combination with the DECP regimen for relapsed/refractory multiple myeloma, currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments [Phase 3]
Clinical trial update announcing a Phase 3 study of elranatamab alone and with daratumumab for multiple myeloma, currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-27Clinical Trial Update: Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
This clinical trial update discusses response-based dose reduction of Linvoseltamab in relapsed/refractory multiple myeloma across Phase 1 a…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) [Phase 2]
The CAPTUR Phase 2 trial by the Canadian Cancer Trials Group is currently recruiting and evaluates profiling and targeted agent utilization …
-
FDA approval · 2026-03-25FDA Approved: ELREXFIO — Supplemental Application (U.S. Pharmaceuticals)
FDA approved a supplemental application for ELREXFIO (elranatamab-BCMM) filed by U.S. Pharmaceuticals.
-
EMA approval · 2026-03-25EMA Authorised: Bortezomib Accord (bortezomib) — Accord Healthcare S.L.U.
EMA authorised Bortezomib Accord for the treatment of multiple myeloma; the product is marketed by Accord Healthcare S.L.U. with a decision …
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant [Phase 3]
Phase 3 clinical trial comparing linvoseltamab to standard treatment in adults with multiple myeloma who are not transplant-eligible to eval…
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation [Phase 3]
A Phase 3 clinical trial is evaluating teclistamab with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy …
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers [NA]
A clinical trial is recruiting to test an AI-generated, personalized question prompt list designed to help patients with lymphoma or multipl…
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma [Phase 3]
This Phase 3 trial compares GR1803 Injection against the DPd regimen (daratumumab, pomalidomide, and dexamethasone) in relapsed or refractor…
-
CLINICAL_TRIALS trial_result · 2026-03-25Clinical Trial Update: Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma [Phase 1]
Phase 1 safety and tolerability study of CFT7455 in relapsed/refractory non-Hodgkin's lymphoma and multiple myeloma is currently active but …
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/2 clinical trial is currently recruiting to evaluate a combination of two approved drugs with one experimental drug in patients wi…
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma [Phase 2]
Clinical trial update for a Phase 2 study evaluating a quadruplet regimen of daratumumab, carfilzomib, lenalidomide, and dexamethasone in ne…
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction [Phase 2]
Phase 2 trial evaluating PD-1Ab21-BCMA CAR-T therapy as consolidation for multiple myeloma with renal dysfunction; the study is currently re…